Charles River Laboratories International Inc

CRL

Add to Watchlist

177.620USD

-4.070-2.24%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

Charles River Laboratories International Inc's Score

Industry at a Glance

Industry Ranking

12 / 384

Overall Ranking

89 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Charles River Laboratories International Inc Highlights

StrengthsRisks

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -47.77, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 55.69M shares, decreasing 13.16% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 3.00 shares of this stock.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

211.716

Target Price

+16.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Charles River Laboratories International Inc is 7.32, ranking 99 out of 384 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 995.83M, representing a year-over-year increase of 1.18%, while its net profit experienced a year-over-year increase of 158.28%.

Score

Industry at a Glance

Previous score

7.32

Change

0



Financials

7.35

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.23

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.49

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.09

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Charles River Laboratories International Inc is 8.94, ranking 3 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -47.77, which is -2085.94% below the recent high of 948.76 and -424.67% above the recent low of -250.66.

Score

Industry at a Glance

Previous score

8.94

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/384

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Charles River Laboratories International Inc is 7.89, ranking 269 out of 384 in the Biotechnology & Medical Research industry. The average price target is 197.00, with a high of 211.00 and a low of 157.42.

Score

Industry at a Glance

Previous score

7.89

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Charles River Laboratories International Inc is 7.28, ranking 112 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 194.14 and the support level at 161.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.83

Change

-1.55

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Charles River Laboratories International Inc is 10.00, ranking 1 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 112.86%, representing a quarter-over-quarter decrease of 12.58%. The largest institutional shareholder is The Vanguard, holding a total of 5.73M shares, representing 11.61% of shares outstanding, with 6.40% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.88M

+2.00%

Allspring Global Investments, LLC

2.00M

-8.37%

State Street Investment Management (US)

1.87M

+2.21%

Invesco Advisers, Inc.

1.78M

+1113.97%

Wellington Management Company, LLP

1.75M

-45.17%

Harris Associates L.P.

Star Investors

1.68M

+13.88%

Dimensional Fund Advisors, L.P.

1.44M

+27.53%

Fidelity Management & Research Company LLC

1.55M

+293.11%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Charles River Laboratories International Inc is 7.37, ranking 13 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Charles River Laboratories International Inc

CRL

7.94 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AnaptysBio Inc

ANAB

8.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment